This section of the website is for UK Healthcare Professionals only. 
If you are not a Healthcare Professional, please click here.

ELATIVE Efficacy data

Primary Biliary Cholangitis (PBC) Internal Link

With IQIRVO 13x more patients had a biochemical response vs treatment with UDCA alone5*† as well as a rapid and sustained ALP reduction from baseline in just 4 weeks – sustained through to 52 weeks1,5†

IQV-UK-000159 | January 2025

ELATIVE Efficacy data
Explore more Primary Biliary Cholangitis (PBC) Resources

Explore more Primary Biliary Cholangitis (PBC) Resources

Browse